In addition, based on our results, monitoring SELENOP levels alongside key biomarkers, including hormonal markers (AR, ESR1, THRB) and those associated with lipid/triglyceride metabolism (PPARA, APOC3, APOA5), may offer a comprehensive approach for refining risk stratification and guiding personalized treatment strategies in liver cancer. This evidence concerns the gene PPARA and liver cancer.